StockData
Silexion Therapeutics Corp logo

Silexion Therapeutics Corp (SLXN) stock

SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.44−0.21 (-12.73%)

Close on Nov 18, 2026Market cap $868.40KP/E –Yield –

Silexion Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Silexion Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$13.52M. For fiscal 2025 it was -$11.63M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.63M–
FY2024Dec 31, 2024-$12.57M–
FY2023Dec 31, 2023-$4.68M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.68M–
Q2 FY2026Jun 30, 2026-$3.68M–
Q1 FY2026Mar 31, 2026-$2.75M–
Q4 FY2025Dec 31, 2025-$4.41M–
Q3 FY2025Sep 30, 2025-$3.29M–
Q2 FY2025Jun 30, 2025-$2.28M–
Q1 FY2025Mar 31, 2025-$1.65M–
Q4 FY2024Dec 31, 2024-$1.90M–
Q3 FY2024Sep 30, 2024-$8.04M–
Q2 FY2024Jun 30, 2024-$1.39M–
Q1 FY2024Mar 31, 2024-$1.25M–
Q4 FY2023Dec 31, 2023-$1.73M–
Q3 FY2023Sep 30, 2023-$731.00K–
Q2 FY2023Jun 30, 2023-$1.41M–

More Silexion Therapeutics figures

See a number that looks wrong?